Xenon Seven

Xenon Seven

Senior Manager/Associate Director, Access Marketing

Boston · Director

Sponsorship not specifiedDetected 124 days ago
RESTClinical TrialsPatient CareResearchCommunicationOrganizational Skills

About the role

  • We are seeking a Senior Manager/Associate Director, Access Marketing, to join our team.
  • This person will be an integral member of the US Market Access team, responsible for executing the azetukalner access strategy to ensure payer and patient access.
  • This individual will play a pivotal role in orchestrating communication and alignment across the market access, marketing, and sales to ensure optimal azetukalner coverage and pull-through efforts.

Responsibilities

  • Support the execution of pre-launch and post-launch market access strategy and tactical plan
  • Lead the development of patient- and office-facing materials and enhance resources to support patient access
  • Develop and gain approvals for access marketing tactics and materials that effectively communicate the value story.
  • Collaborate across the patient access team to identify opportunities for evolving office and patient support messaging
  • Develop and propose short- and long-term objectives for the function in accordance with overall Company strategies and plans
  • Recruit, lead, direct, develop, coach and evaluate direct reports, if any, in accordance with the Company's Human Resource policies and practices

Requirements

  • 3+ (Senior Manager level) or 5+ years (Associate Director level) of experience in pharma or biotech industry, including 3+ years of related market access or marketing experience.
  • Strong understanding of US payer and channel market dynamics and how managed care organizations make decisions across commercial and government channels.
  • Ability to take resources, concepts, and tools effectively through internal PRC review processes.
  • Strong analytical skills with proven ability to effectively analyze data to determine trends and inform strategy
  • Up to 20% travel may be required based upon business needs
  • Some international travel may be required
  • Minimum Bachelor's degree required; advanced degree preferred (ex. MBA).
  • US market access launch experience with pharmacy benefit products preferred.
  • A highly organized and self-motivated individual who has demonstrated the ability to prioritize and manage multiple projects to meet project objectives, timelines, and budget.
  • Proven ability to drive results at a high level of quality.
  • Driven by intellectual curiosity, "roll-up your sleeves" attitude, and highly effective despite ambiguity.
  • Excellent oral and written communication skills and presentation skills, especially with senior leadership.

Nice to have

  • Minimum Bachelor's degree required
  • advanced degree preferred (ex.

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Benefits

  • Collaborate with medical affairs and HEOR/RWE to inform real-world evidence generation plans and ensure evidence generation activities meet the needs of payers

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.